

Antifungal activity of a toothpaste containing Ganoderma lucidum against Candida albicans - an in vitro study

Aarati Nayak* Ranganath N Nayak† Kishore Bhat‡

*MDS Professor and Head, Dept. of Periodontology, †MDS Professor and Head, Dept. of Oral & Maxillofacial Surgery, ‡Professor and Head, Dept. of Microbiology, Maratha Mandal's. N.G.H.Institute of Dental Sciences & Research Centre, Belgaum – 590010, Karnataka, India.

Abstract:

Introduction: Candida albicans is the most common oral fungus associated with oral candidial infections. Various antifungal agents are in use and the search is on for more agents showing anti candidial properties. Ganoderma lucidum has been in use in Traditional Chinese Medicine for years. Literature supports the use of this Ganoderma lucidum as a medicinal mushroom for its antimicrobial, antiviral properties.

Objectives: Varying concentrations of a toothpaste containing Ganoderma lucidum was tested in vitro for its antifungal properties against Candida albicans.

Method: The activity of a Ganoderma containing toothpaste against Candida albicans was tested by serial broth dilution method and was expressed by minimum inhibitory concentration (MIC).

Results: The toothpaste exhibited antifungal properties against the tested organism. The MIC value of Candida albicans was found to be less than 02 mgm /ml.

Key words: Ganoderma lucidum, toothpaste, Candida albicans, serial broth dilution, MIC.

P- ISSN
0976 – 7428

E- ISSN
0976 – 1799

*Journal of
International
Oral Health*

Oral & Maxillofacial
Surgery

Original Research

Received: Apr, 2010

Accepted: July, 2010

Bibliographic listing:

EBSCO Publishing

Database, Index

Copernicus, Genamics

Journalseek Database

Introduction:

In a healthy host, opportunistic fungal pathogens are commensal fungi commonly colonizing human mucosal surfaces. *Candida albicans* is one such opportunistic human pathogen that colonizes at several anatomically distinct sites such as oral cavity, skin, gastrointestinal tract and the vagina. *Candida albicans* has been found in all ages especially in the oral cavity of babies and geriatric age groups. Over-proliferation of *Candida albicans* and its infiltration into the mucosal or cutaneous surface results in a pathogenic infection. This infection is known as Candidiasis. Oral Candidiasis can occur in patients with long term use of antibiotics in immune-compromised hosts and in patients undergoing cytotoxic chemotherapy and radiotherapy. This could also predispose the patient to systemic candidial infection.

Many of the currently available antifungal drugs have undesirable side effects and lead to the rapid development of drug resistance, causing profound effects on human health¹. This has necessitated the need for discovering new effective antifungal drugs. Traditional medicine has a huge treasury of herbs and remedies that can be tapped as a source for obtaining antifungal agents from the plant, animal and fungal kingdom after scientific research.

Ganoderma lucidum is a Basidiomycetes fungus belonging to the family Polyporaceae.² It has been in use for thousands of years for its medicinal properties in Traditional Chinese Medicine.³ It is known to have many biologically active components like triterpenes^{4,5}, polysaccharides^{6,7}, ganoderic acids⁵, and so on, giving it, its antimicrobial⁸⁻¹³, antiviral^{10,14-17}, immunomodulatory¹⁵, antioxidant¹⁸, antitumour¹⁹ and anticancer²⁰ properties. As the antimicrobial and antiviral activity of *Ganoderma* has already been documented scientifically, with just a few mentions in scientific papers regarding its antifungal activity on human pathogens, it was decided that a preliminary study to observe its

antifungal effects on *Candida albicans* would be in order.

Toothpastes are the most common vehicles for delivery of drugs to the oral cavity. This preliminary study was aimed at determining the Minimum Inhibitory Concentration (MIC) of one such toothpaste containing *Ganoderma lucidum* * on *Candida albicans* in vitro by serial broth dilution method. This toothpaste does not contain any other constituents that could demonstrate anticandidial properties.

Materials and Methods:

A standard procedure for performing the MIC test was followed²¹. The standard strain of *Candida albicans* used in this study was ATCC 2091. Sabouraud dextrose broth, *Ganoderma lucidum* containing paste, sterile MIC tubes and micropipettes were the other armamentarium used.

Procedure: Revival of the organism – The *Candida albicans* strain from the stock was revived by plating on blood agar medium. After overnight incubation at 37⁰ C, isolated colonies were selected and the identity of the organism was confirmed. Isolated colonies were transferred to sterile Sabouraud dextrose broth and once again incubated overnight. The growth concentration was adjusted to 10⁵ organisms / ml by using 0.5 McFarland's turbidity standard.

To prepare stock of the toothpaste, one gram of the toothpaste was added to one ml. of sterile saline in a sterile vial.

*A branded proprietary product (*Ganoderma lucidum* toothpaste manufactured by DXN Industries (M) SDN, BHD. Malaysia) containing *Ganoderma lucidum* in a food gel base with menthol is available worldwide since 1993.

Two hundred µl of the Sabouraud dextrose broth was added in ten MIC tubes. In the first MIC tube containing 200 µl broth, 200 µl of stock was added. After mixing well, 200 µl was transferred to the second MIC tube. This was continued till the last

(10th) tube. From the last tube 200 µl final solution was discarded. By following this serial dilution, the concentration of the paste was achieved as the following – 500, 250, 125, 62.5, 31.25, 16, 8, 4, 2 mgm. /ml. respectively.

To each of the ten such prepared MIC tubes with varying concentrations, 200 µl of the earlier prepared strain of *Candida albicans* was added, such that the final volume per tube was 400 µl. The tubes were then incubated for 48 hours at 35⁰ C.

After the incubation, the MIC values were determined by visual inspection of the tubes. With the MIC tubes, positive and negative controls were put up. Positive control containing broth plus candidial strain showed turbidity and negative control containing broth only appeared clear. In the tubes tested, the last tube with clear supernatant was considered to be without any growth and taken as MIC value.

Turbidity in the MIC tube indicated growth of the fungus implying that it was resistant to the toothpaste.

Results

Results, as shown in Table 1, indicated that the MIC value for *Candida albicans* was less than 02 mgm. /ml.

Discussion:

The incidence of *Candida albicans* isolated from the oral cavity has been reported to be 45% in neonates,²² 45%–65% of healthy children,²³ 30%–45% of healthy adults^{24,25}, 50%–65% of people who wear removable dentures,²⁵ 65%–88% in those residing in acute and long term care facilities,²⁵⁻²⁷ 90% of patients with acute leukemia undergoing chemotherapy,²⁸ and 95% of patients with HIV²⁹. *Candida* species now rank as the fourth most common cause of nosocomial bloodstream infections in the United States and the attributable mortality rate is 30%³⁰.

Advances in medical technology, chemotherapeutics, cancer therapy, and organ transplantation have greatly reduced the morbidity and mortality of life-threatening diseases. Patients who are critically ill and in medical and surgical ICUs have been the prime targets for opportunistic nosocomial fungal infections, primarily due to *Candida* species. On a daily basis, virtually all physicians are confronted with a positive *Candida* isolate obtained from one or more anatomical sites. High-risk areas for *Candida* infection include neonatal, paediatric, and adult ICUs, both medical and surgical³¹.

Table 1 – MIC of the tested organism

| Organism | Concentration of the toothpaste containing Ganoderma lucidum in mg / ml. | | | | | | | | |
|-------------------------|--|-----|-----|------|-------|----|----|----|----|
| | 500 | 250 | 125 | 62.5 | 31.25 | 16 | 08 | 04 | 02 |
| <i>Candida albicans</i> | S | S | S | S | S | S | S | S | S |

S = Sensitive R = Resistant

Oropharyngeal candidiasis can manifest as pseudomembranous candidiasis, acute atrophic candidiasis, chronic hyperplastic candidiasis, chronic atrophic candidiasis, median rhomboid glossitis and angular cheilitis³². Dentures have always been found to be a breeding ground for *Candida albicans*. Astrid VandenAbbeele et al³³ in their study observed that screening of upper prostheses demonstrated *Candida* colonisation of upper prosthesis in 75.9% of individuals. The most frequent species isolated were *Candida albicans* 77.9% of the positive cultures, *Candida glabrata* (44.1%) and *Candida tropicalis* (19.1%). HirokowiNikawa et al³⁴ concluded that denture plaque (plaque on denture) containing candida could cause not only oral candidiasis, like oral thrush or denture-induced stomatitis, but also caries, root caries and periodontitis of abutment teeth.

In HIV disease, up to 90% of HIV+ persons have a symptomatic episode of oropharyngeal candidiasis. Both innate resistance and acquired immunity play some role in maintaining *C. albicans* in the commensal state and protecting the systemic circulation³⁵

Abate screened about 60 different basidiomycetes cultures for antimicrobial secondary metabolites. Amongst these the culture filtrate extract of the polypore, *G. lucidum* produced the most effective antifungal compounds. The minimal inhibitory concentration (MIC) of 201A against *Candida albicans* was less than 1 mcg/ml³⁶. The Ganoderma containing toothpaste that was tested by us demonstrated a MIC of 2 mgm/ml against *Candida albicans*. This is reasonable considering that the toothpaste contains Ganoderma in a food gel base with no other ingredients with antifungal activity.

Hexiang Wang³⁷ isolated a 15-kDa antifungal protein, designated Ganodermin, from *Ganoderma lucidum*. Ganodermin inhibited the mycelial growth in the phytopathogenic fungi *B. cinerea*, *F. oxysporum* and *P. piricola*. It will have to be ascertained in future studies, whether

Ganodermin has a similar antifungal activity against *Candida albicans*.

Very few bioactive proteins, such as a lectin³⁸ and a ribonuclease³⁹ have been isolated from *G. lucidum*. There is scant literature on the antifungal action of *Ganoderma lucidum* on other fungi.

Both innate resistance and acquired immunity play some role in maintaining *C. albicans* in the commensal state and protecting the systemic circulation. Polymorphonuclear leucocytes are critical for protection against systemic infections, whereas cell-mediated immunity (CMI) by Th1-type CD4⁺ T-cells is important for protection against mucosal infections³⁵. Fidel³⁵ recently found that epithelial cells from saliva and vaginal lavages of healthy individuals inhibit the growth of *Candida* in vitro. This epithelial cell anti-*Candida* activity requires cell contact by viable cells with no role for soluble factors, including saliva. Interestingly, oral epithelial cells from HIV positive persons with OPC had significantly reduced activity, indicating some protective role for the epithelial cells. TNF- α was also implicated as an important mediator in the recovery from oropharyngeal candidiasis⁴⁰. *Candida albicans* triggers interleukin-6 and interleukin-8 responses by oral fibroblasts in vitro. The secretion of proinflammatory cytokines - interleukin-6 and interleukin-8 by oral mucosal fibroblasts in response to *C. albicans* suggests that these cells have the potential to enhance the host defense against this organism in vivo. This may have important implications in controlling fungal overgrowth in the oral cavity⁴¹.

Virulence factors in *Candida albicans* have been attributed to the utilization of several genes whose functions in adhesion, proteinases secretion, hyphal formation and phenotypic switching are required for their virulence¹. Taking into consideration all these local factors, we thought it would be prudent to use a Ganoderma containing toothpaste as it could prove convenient and useful for application on mucosa and dentures and toothbrushing

Hossain et al⁴² concluded that carious teeth may constitute an ecologic niche for *C. albicans* potentially responsible for recurrent oral and non-oral candidiasis.

Fagade&Oyelade in their study⁴³ on testing ethanolic extracts of *Ganodermalucidum* on various microorganisms found that the MIC of *Candida albicans* was 750 mgm/ml. In our study, we tested a toothpaste containing *Ganodermalucidum* against *Candida albicans*. It was highly sensitive with an MIC of less than 2 mgm. / ml. This is because the toothpaste contains spore powder, whereas Fagade used ethanolic extracts of the fruiting body. Therefore this toothpaste could be highly effective in patients with HIV infections, patients undergoing radiotherapy or chemotherapy, immunocompromised individuals, in high risk areas such as medical and surgical ICU's, as a local application on dentures and oropharyngeal candidiasis. However a clinical study to corroborate these laboratory findings is suggested.

References:

- 1) Yun-Liang Yang. Virulence factors of *Candida* species. *J Microbiol Immunol Infect* 2003; 36: 223-8.
- 2) Hibbett DS et al. A higher level phylogenetic classification of the Fungi *Mycol Res* 2007; 111(5): 509-47.
- 3) Wasson RG. Divine mushroom of immortality: Los Angeles: Harcourt, Brace, Jovanovich 1968; 83-96.
- 4) Zhu M, Chang Q, Wong LK, Chong FS, Li RC. Triterpene antioxidants from *Ganodermalucidum*. *Phytother Res* 1999; 13 (6): 529-31.
- 5) Luo J, Zhao YY, Li ZB. A new lanostane – type triterpene from the fruiting bodies of *Ganodermalucidum*. *J Asian Nat Prod Res* 2002; 4 (2): 129-34.
- 6) Hsu MJ, Lee SS, Lee ST, Lin WW. Signaling mechanisms of enhanced neutrophil phagocytosis and chemotaxis by the polysaccharide purified from *Ganodermalucidum*. *Br J Pharmacol* 2003; 139(2): 289-98.
- 7) Fang JN, Bao XF, Wang XS, Dong Q, Li XY. Structural Features of Immunologically Active Polysaccharides from *Ganodermalucidum*. *Phytochemistry* 2002; 59(2): 175-81.
- 8) Yoon SY, Eo SK, Kim YS, Lee CK, Han SS. Antimicrobial activity of *Ganodermalucidum* extract alone and in combination with some antibiotics. *Arch Pharm Res* 1994; 17(6): 438-42.
- 9) Wasser SP, Weis A. Medicinal Mushrooms. *Ganodermalucidum*, (Curtis: Fr.), P Karst. In: Nevo, E, Editors. *Medicinal Mushrooms* Haifa, Israel: PeledfusPubl House 1997: 39.
- 10) Gao Y, Zhou Sh, Huang M, Xu A. Antibacterial and antiviral value of the genus *Ganoderma* P. Karst. species (*Aphyllorphomycetidae*) : a review. *Int J Med* 2003; 5(3): 235-46.
- 11) Smith J, Rowan N, Sullivan R. *Medicinal Mushrooms: Their Therapeutic Properties and Current Medical Usage with Special Emphasis on Cancer Treatment; Special Report Commissioned by Cancer Research UK.* The University of Strathclyde in Glasgow: 2003; 5 (3): 235-46.
- 12) Suay I, Arenal F, Asensio FJ, Basilio A, Cabello MA, Diez MT et al. Screening of Basidiomycetes for antimicrobial activities. *Antonie van Leeuwenhoek* 2000; 78: 129-39.
- 13) Jann Ichida. *Healthy Mushrooms: Antibacterial Effects of Medicinal Shiitake (Letinulaedodes) and Reishi/Ling Chi (Ganodermalucidum) Mushroom Extracts.* 106th General Meeting of the American Society for Microbiology. May 21-25, 2006, Orlando, Florida.
- 14) Eo SK, Kim YS, Lee CK, Han SS. Antiviral activities of various water and methanol soluble substances isolated from *Ganodermalucidum*. *J Ethnopharmacol* 1999; 68(1-3): 129-36.
- 15) Van der Hem LG, Van der Vliet JA, Bocken CF, Kino K, Hoitsma AJ, Tax WJ. Ling Zhi-8: studies of a new immunomodulating agent. *Transplantation* 1995; 60(5): 438-43.

- 16) Min BS, Nakamura N, Miyashiro H, Bae KW, Hattori M. Triterpenes from the spores of *Ganodermalucidum* and their inhibitory activity against HIV-1 protease. *Chem Pharm Bull* 1998; 46(10): 1607-12.
- 17) El-Mekawy S, Meselhy MR, Nakamura N, Tezuka Y, Hattori M, Kakiuchi N et al. Anti-HIV-1 and anti-HIV-1-protease substances from *Ganodermalucidum*. *Phytochemistry* 1998; 49(6): 1651-7.
- 18) Mau JL, Lin HC, Chen CC. Antioxidant properties of several medicinal mushrooms. *J Agric Food Chem* 2002; 50(21): 6072-7.
- 19) Wang SY, Hsu ML, Hsu HC, Tzeng CH, Lee SS, Shiao MS, Ho CK. The anti-tumour effect of *Ganodermalucidum* is mediated by cytokines released from activated macrophages and T lymphocytes. *Int J Cancer* 1997; 70(6): 699-705.
- 20) Sliva D, Labarrere C, Slivova V, Sedlak M, Lloyd FP Jr, Ho NW. *Ganodermalucidum* suppresses motility of highly invasive breast and prostate cancer cells. *Biochem. Biophys. Res. Commun.* 2002; 298(4): 603-12.
- 21) Koneman EW, Allen SD, Janda WM, Schreckenberger PC, Winn Jr WC. *Colour Atlas and textbook of Diagnostic Microbiology* 5th ed. Philadelphia: Lippincott Williams & Wilkins 1997: 1320-22.
- 22) Manning DJ, Coughlin RP, Poskit EM. *Candida* in mouth or on dummy? *Arch Dis Child* 1985; 60: 381-2.
- 23) Berdicevsky I, Ben-Aryeh H, Sazargel R et al. Oral *Candida* in children. *Oral Surg Oral Med Oral Pathol* 1980; 57: 37-40.
- 24) Lucas VS. Association of psychotropic drugs, prevalence of denture-related stomatitis and oral candidosis. *Community Dent Oral Epidemiol* 1993; 21: 313-16.
- 25) Arendorf TM, Walker DM. The prevalence and intra-oral distribution of *Candida albicans* in man. *Arch Oral. Biol* 1980; 25: 1-10.
- 26) Cumming CG, Wight C, Blackwell CL et al. Denture stomatitis in the elderly. *Oral Microbiol Immunol* 1990; 5: 82-5.
- 27) Holbrook WP, Hjorleifsdottir DV. Occurrence of oral *Candida albicans* and other yeast-like fungi in edentulous patients in geriatric units in Iceland. *Gerodontology* 1986; 2: 153-6.
- 28) Rodu B, Carpenter JT, Jones MR. The pathogenesis and clinical significance of cytologically detectable oral *Candida* in acute leukaemia. *Cancer* 1988; 62: 2042-6.
- 29) Dupont B, Graybill JR, Armstrong D et al. Fungal infections in AIDS patients. *J Med Vet Mycol* 1992; 30 (suppl 1): 19-28.
- 30) Wenzel RP. Nosocomial candidemia: risk factors and attributable mortality. *Clin Infect Dis* 1995; 20: 1531-4.
- 31) Pappas PG, Rex JH, Lee J et al. A prospective observational study of candidemia: epidemiology, therapy, and influences on mortality in hospitalized adult and pediatric patients. *Clin Infect Dis* 2003; 37(5): 634-43.
- 32) Apkan A, Morgan R. Oral candidiasis - *Postgraduate Medical Journal* 2002; 78(922): 455-9.
- 33) Abbeele AV, De Meel H, Ahariz M, Perraudin JP, Beyer I, Philippe C. Denture Contamination by Yeasts in the Elderly. *Gerodontology* 2008; 25(4): 222-8.
- 34) Nikawa H, Hamada T, Yamamoto T. Denture Plaque - Past and Recent Concerns. *Journal of Dentistry* 1998; 26(4): 299-304.
- 35) PL Fidel. Immunity to *Candida*. *Oral Diseases* 2002; 8(S2): 69-75.
- 36) Abate D, Bitew A. Antifungal metabolites from submerged culture of *Ganoderma Lucidum* (Polypore). *Ethiopian Journal of Health Development.* 1994; 8(1): 63-70.
- 37) Wanga H. Ganodermin, an antifungal protein from fruiting bodies of the medicinal mushroom *Ganodermalucidum*. *Peptides* 2006; 27: 27-30.
- 38) Tanaka S, Ko K, Kino K, Tsuchiya K, Yamashita A, Murasugi A et al. An immunomodulatory protein from a fungus *Ganodermalucidum* having similarity to immunoglobulin variable region. *J Biol Chem* 1989; 264: 16372-7.

- 39) Wang HX, Ng TB, Chiu SW. A distinctive ribonuclease from fresh fruiting bodies of the medicinal mushroom. *Ganoderma lucidum*. *Biochem Biophys Res Commun* 2004; 314: 519-22.
- 40) Farah CS, Gotjamanos T, Seymour GJ, Ashman RB. Cytokines in the oral mucosa of mice infected with *Candida albicans*. *Oral Microbiology and Immunology* 2002; 17(6): 375-8.
- 41) Dongari-Bagtzoglou A, Wen K, Lamster IB. *Candida Albicans* triggers interleukin-6 and interleukin-8 Responses by Oral fibroblasts in Vitro *Oral Microbiology and Immunology* 1999; 14 (6): 364.
- 42) Hossain H, Ansari F, Schulz-Weidner N, Wetzel WE, Chakraborty T, Domann E. Clonal identity of *Candida albicans* in the oral cavity and the gastrointestinal tract of pre-school children. *Oral Microbiology and Immunology* 2003; 18 (5): 302-8.
- 43) Fagade O E, Oyelade AA. A comparative study of the antibacterial activities of some wood-decay fungi to synthetic antibiotic discs. *EJEAFCh* 2009; 8 (3): 184-8.

Source of Support: Nil

Conflict of Interest: Not Declared